- Secures 2 years of inventory, signs contract with local CMO for U.S. sales products
- 카지노 바카라 considers acquiring company with U.S.-based production facilities
[by Ji, Yong Jun] Celltrion announced on July 9 that it has established a contingency response strategy aimed at minimizing the potential impact of U.S. President Donald Trump’s proposed pharmaceutical tariff policy. On the same day, President Trump declared his intention to implement tariffs on pharmaceutical products, allowing for a grace period of up to one year and six months.
Celltrion has been closely monitoring developments related to the imposition of pharmaceutical tariffs in the United States and has prepared response strategies for the short-, mid-, and long-카지노 바카라. As a short-카지노 바카라 measure, the company has secured a two-year supply of inventory and intends to consistently maintain this level of stock to ensure supply chain stability.
In the mid-카지노 바카라, Celltrion has completed a contract with a U.S.-based contract manufacturing organization (CMO) to enable local production of products destined for the U.S. market. For the long 카지노 바카라, the company is considering the acquisition of a manufacturing facility in the U.S. Celltrion stated that it will provide detailed information to shareholders once these plans are concretized.
“As mentioned during the shareholders’ meeting in May, the company is preparing a response system in the United States that addresses not only the short-카지노 바카라 challenges but also the mid- to long-카지노 바카라 contingencies,” a Celltrion official said. “Our goal is to complete all necessary preparations by the end of 2026 to ensure that the U.S. pharmaceutical tariff policy, regardless of its timing or scale, has no adverse impact on the company. We will continue to keep shareholders informed of our progress.”